发明名称 |
NEW USE OF L-HISTIDINE AND DERIVATIVES THEREOF |
摘要 |
The present invention discloses the use of L-Histidine to reduce Gadolinium accumulation into target organs, preventing its toxic effects, after administration of gadolinium based contrast agents. The invention thus, also disclose the use of L-Histidine to prevent the NSF syndrome in patients with renal functionality impairment. A kit of part is also disclosed by the use of which toxicity associated to free Gd3+, deriving from GDBCA, is prevented by oral administration of L-histidine before administration of the contrast agent. A method for the prevention of toxic metal accumulation which consists in the administration, preferably by the oral route, of L-Histidine is also disclosed. L-Histidine is preferably administered a s a single oral dose comprised from 0.2-20 g. |
申请公布号 |
US2014155449(A1) |
申请公布日期 |
2014.06.05 |
申请号 |
US201214235128 |
申请日期 |
2012.07.24 |
申请人 |
Zsolt Baranyai;Brücher Ernö;Bussi Simona;Maiocchi Alessandro;Uggeri Fulvio |
发明人 |
Zsolt Baranyai;Brücher Ernö;Bussi Simona;Maiocchi Alessandro;Uggeri Fulvio |
分类号 |
A61K31/4172;A61K31/28 |
主分类号 |
A61K31/4172 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of preventing Gadolinium (Gd3+) accumulation in a patient's target organ after a GDBCA (Gadolinium Based Contrast Agent) administration comprising:
administering L-Histidine or a derivative thereof before or simultaneous with administration of a GDBCA (Gadolinium Based Contrast Agent).
|
地址 |
Debrecen HU |